MapLight Therapeutics (MPLT) EPS (Weighted Average and Diluted) (2024 - 2025)
MapLight Therapeutics' (MPLT) quarterly EPS (Weighted Average and Diluted) came in at $87.14 in Q4 2025, up 411.1% year-on-year from $17.05 in Q4 2024, and up 334.37% quarter-over-quarter from -$37.18 in Q3 2025.
MapLight Therapeutics (MPLT) EPS (Weighted Average and Diluted) (2024 - 2025) Analysis & Trends
MapLight Therapeutics has disclosed EPS (Weighted Average and Diluted) across 2 years of filings, most recently posting $87.14 for Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at $87.14, up 411.1% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.13 (changed N/A YoY), and the FY2025 annual result was -$18.56, up 82.39% from the prior year.
- EPS (Weighted Average and Diluted) came in at $87.14 for Q4 2025 at MapLight Therapeutics, up from -$37.18 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $87.14 in Q4 2025 to a low of -$37.18 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | MapLight Therapeutics | 248.88 Mn | 248.88 Mn | - | 87.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 87.14 |
| Sep 30, 2025 | -37.18 |
| Dec 31, 2024 | -28.01 |
| Sep 30, 2024 | -25.08 |